Regarding the mechanism of action and clinical properties of bronchodilators, all of the following statements are correct EXCEPT:

Explanation

## Mechanism of Action of Bronchodilators ### Beta-2 Agonists **Key Point:** β~2~-agonists bind to β~2~-adrenergic receptors on airway smooth muscle, activating adenylyl cyclase via G-protein coupling. This increases intracellular cAMP, leading to smooth muscle relaxation and bronchodilation. This statement is **correct**. ### Anticholinergic Agents **Key Point:** Muscarinic antagonists (ipratropium, tiotropium) block M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. They are particularly effective in COPD. This statement is **correct**. ### Methylxanthines (Theophylline) **High-Yield:** Theophylline has **multiple mechanisms of action**, not just phosphodiesterase inhibition: 1. **Phosphodiesterase inhibition** (at therapeutic doses) → ↑ cAMP 2. **Adenosine receptor antagonism** → reduces bronchoconstriction 3. **Calcium channel modulation** → reduces smooth muscle contractility 4. **Anti-inflammatory effects** → reduces airway inflammation 5. **Respiratory center stimulation** → increases minute ventilation The statement claiming phosphodiesterase inhibition is the **sole mechanism** is **incorrect**. ### Long-Acting Beta-2 Agonists (LABAs) **Key Point:** LABAs (salmeterol, formoterol) have a duration of 12–24 hours. **Critical guideline:** LABAs should **never be used as monotherapy** in asthma due to increased risk of asthma-related deaths. They must be combined with inhaled corticosteroids (ICS). This statement is **correct**. ## Summary Table | Agent Class | Mechanism | Key Limitation | | --- | --- | --- | | Short-acting β~2~-agonists (SABA) | ↑ cAMP via adenylyl cyclase | Tachyphylaxis with overuse | | Long-acting β~2~-agonists (LABA) | ↑ cAMP; 12–24 hr duration | **Never monotherapy in asthma** | | Anticholinergics | Block M3 receptors | Slower onset than β~2~-agonists | | Methylxanthines | **Multiple mechanisms** (not just PDE inhibition) | Narrow therapeutic index | **Clinical Pearl:** The question tests knowledge that theophylline is a **multi-target drug**, not a single-mechanism agent. This is a common misconception among students who oversimplify its action to phosphodiesterase inhibition alone.